News

July 15, 2026

Cellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executives
New chief strategy officer and chief marketing officer join to help lead the company’s next phase of growth at the frontier of AI and biology.

May 11, 2026

CEO Perspective: A defining moment for Cellular Intelligence
We have entered into an agreement with Novo Nordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease.

May 11, 2026

Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson’s Cell Therapy
Cellular Intelligence has secured global rights to Novo Nordisk’s Parkinson’s program, a clinical-stage allogeneic cell therapy for Parkinson's disease with FDA Fast Track Designation.

January 7, 2026

Somite Becomes Cellular Intelligence, as It Builds the First Universal Virtual Cell-Signaling Model
New white paper details key technical milestones and validation of the company’s proprietary, capsule-based platform to accelerate breakthroughs across human health.

August 20, 2025

Somite.ai announces strategic investment from AMD Ventures to accelerate foundation models for cell therapy
Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures.

May 13, 2025

Somite raises over $47M Series A to revolutionize cell therapy with foundation models
Somite builds foundation models for human stem cells. We’ve just raised over $47M in Series A funding led by Khosla Ventures to accelerate development of DeltaStem, our foundation model to produce any cell type for any person.